Morgan Stanley Mersana Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 357,597 shares of MRSN stock, worth $3.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

357,597

Previous 307,130 16.43%

Holding current value

$3.62 Million

Previous $104,000 2.88%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$0.26 - $0.41 $13,121 - $20,691	50,467 Added 16.43%	357,597 $107,000
Q1 2025 May 15, 2025	SELL	$0.34 - $1.4 $304,716 - $1.25 Million	-896,226 Reduced 74.48%	307,130 $104,000
Q4 2024 Feb 14, 2025	SELL	$1.42 - $2.68 $228,421 - $431,104	-160,860 Reduced 11.79%	1,203,356 $1.72 Million
Q3 2024 May 14, 2025	SELL	$1.23 - $2.25 $1.12 Million - $2.04 Million	-908,378 Reduced 39.97%	1,364,216 $2.58 Million
Q3 2024 Nov 14, 2024	SELL	$1.23 - $2.25 $1.12 Million - $2.04 Million	-908,378 Reduced 39.97%	1,364,216 $2.58 Million
Q2 2024 May 14, 2025	BUY	$2.0 - $4.45 $2.14 Million - $4.76 Million	1,069,238 Added 88.85%	2,272,594 $4.57 Million
Q2 2024 Oct 17, 2024	SELL	$2.0 - $4.45 $1.34 Million - $2.98 Million	-670,083 Reduced 22.77%	2,272,594 $4.57 Million
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $1.34 Million - $2.98 Million	-670,083 Reduced 22.77%	2,272,594 $4.57 Million
Q1 2024 Oct 17, 2024	BUY	$2.16 - $5.94 $1.45 Million - $3.98 Million	670,083 Added 29.49%	2,942,677 $13.2 Million
Q1 2024 Aug 16, 2024	SELL	$2.16 - $5.94 $2.57 Million - $7.08 Million	-1,191,869 Reduced 28.83%	2,942,677 $13.2 Million
Q1 2024 May 15, 2024	SELL	$2.16 - $5.94 $2.57 Million - $7.08 Million	-1,191,869 Reduced 28.83%	2,942,677 $13.2 Million
Q4 2023 Aug 16, 2024	BUY	$1.11 - $2.34 $2.07 Million - $4.36 Million	1,861,952 Added 81.93%	4,134,546 $9.59 Million
Q4 2023 Feb 13, 2024	BUY	$1.11 - $2.34 $3.49 Million - $7.37 Million	3,148,529 Added 319.32%	4,134,546 $9.59 Million
Q3 2023 Nov 15, 2023	BUY	$1.06 - $3.91 $234,796 - $866,088	221,506 Added 28.97%	986,017 $1.25 Million
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $3.49 Million - $10.8 Million	-1,134,122 Reduced 59.73%	764,511 $2.52 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $562,588 - $987,341	140,647 Added 8.0%	1,898,633 $7.8 Million
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $923,277 - $1.28 Million	163,412 Added 10.25%	1,757,986 $10.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $96,628 - $166,960	20,870 Added 1.33%	1,594,574 $10.8 Million
Q2 2022 Oct 27, 2022	SELL	$2.84 - $5.0 $1.7 Million - $2.99 Million	-597,669 Reduced 27.52%	1,573,704 $7.27 Million
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $1.7 Million - $2.99 Million	-597,669 Reduced 27.52%	1,573,704 $7.27 Million
Q1 2022 Oct 27, 2022	BUY	$3.74 - $6.63 $2.24 Million - $3.96 Million	597,669 Added 37.98%	2,171,373 $8.66 Million
Q1 2022 May 13, 2022	BUY	$3.74 - $6.63 $3.53 Million - $6.25 Million	942,766 Added 76.73%	2,171,373 $8.66 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $3.07 Million - $5.53 Million	560,718 Added 83.95%	1,228,607 $7.64 Million
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $5.72 Million - $9.66 Million	667,889 New	667,889 $6.3 Million

Others Institutions Holding MRSN

# of Institutions

Shares Held

93.8M

Call Options Held

34.3K

Put Options Held

14K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $984M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account